Pesquisar
Nuvalent Inc
NUVLAdicionar à lista de desejos
102.300USD
-2.110-2.02%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
8.08BValor de mercado
PerdaP/L TTM
Mais detalhes de Nuvalent Inc Empresa
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Informações de Nuvalent Inc
Código da empresaNUVL
Nome da EmpresaNuvalent Inc
Data de listagemJul 29, 2021
CEOPorter (James R)
Número de funcionários142
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 29
EndereçoOne Broadway, 14Th Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone18573577000
Sitehttps://www.nuvalent.com/
Código da empresaNUVL
Data de listagemJul 29, 2021
CEOPorter (James R)
Executivos da empresa Nuvalent Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Deborah Miller, J.D., Ph.D.
Dr. Deborah Miller, J.D., Ph.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
65.60K
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.50K
-5.92%
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Outro
46.76%
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
23.45%
Fidelity Management & Research Company LLC
14.19%
Paradigm BioCapital Advisors LP
7.16%
BlackRock Institutional Trust Company, N.A.
5.04%
Vanguard Portfolio Management, LLC
3.40%
Outro
46.76%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.62%
Hedge Fund
38.79%
Investment Advisor/Hedge Fund
21.04%
Individual Investor
2.77%
Venture Capital
2.58%
Private Equity
2.26%
Research Firm
1.46%
Sovereign Wealth Fund
0.78%
Bank and Trust
0.33%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
490
86.91M
118.14%
+5.88M
2025Q4
462
75.27M
104.86%
-2.57M
2025Q3
440
73.50M
109.27%
-4.34M
2025Q2
438
75.09M
113.13%
-1.35M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Deerfield Management Company, L.P.
17.25M
23.57%
-742.57K
-4.13%
Dec 31, 2025
Fidelity Management & Research Company LLC
10.44M
14.27%
+685.62K
+7.03%
Dec 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.2%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.71M
5.06%
+578.29K
+18.49%
Dec 31, 2025
Wellington Management Company, LLP
2.46M
3.36%
+160.96K
+7.00%
Dec 31, 2025
T. Rowe Price Associates, Inc.
2.10M
2.86%
+330.62K
+18.74%
Dec 31, 2025
JP Morgan Asset Management
2.01M
2.75%
+498.40K
+32.96%
Dec 31, 2025
RA Capital Management, LP
1.88M
2.57%
+633.60K
+50.83%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Tema Oncology ETF
4.14%
ALPS Medical Breakthroughs ETF
2.65%
Global X Guru Index ETF
1.57%
State Street SPDR S&P Biotech ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
iShares Health Innovation Active ETF
0.82%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
ProShares Ultra Nasdaq Biotechnology
0.65%
Invesco Nasdaq Biotechnology ETF
0.64%
iShares Biotechnology ETF
0.39%
Ver Mais
Tema Oncology ETF
Proporção4.14%
ALPS Medical Breakthroughs ETF
Proporção2.65%
Global X Guru Index ETF
Proporção1.57%
State Street SPDR S&P Biotech ETF
Proporção1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.86%
iShares Health Innovation Active ETF
Proporção0.82%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.72%
ProShares Ultra Nasdaq Biotechnology
Proporção0.65%
Invesco Nasdaq Biotechnology ETF
Proporção0.64%
iShares Biotechnology ETF
Proporção0.39%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
